Basel, Switzerland-based Novartis agreed to pay $168 per ACL share through a combination of its own shares and "a contingent value cash component," according to a prepared statement from Alcon.
A microchip a day might keep the doctor away: Novartis AG, using technology licensed from Proteus Biomedical, is currently developing the Ingestible Event Marker, a specialized microchip which the company plans to add to pills. When a patient ingests an IEM-enhanced pill, their stomach acids activate the microchip, which then sends data such as heart rate, temperature, and body movements to a dermal patch via Bluetooth connectivity. This patch can then export the data to an EMR, so that it can be accessed by the patient’s doctors.
Highlights fro the world of healthcare:
Tattletale medicine? Novartis AG plans to seek regulatory approval within 18 months for a pioneering tablet containing an embedded microchip that sends information to your doctor about whether you took your medication and how it’s working, according to Reuters.
Alcon Inc. (NYSE:ACL) named Robert Karsunky as its new CFO.
Novartis AG (NYSE:NVS) is now a majority stakeholder in Alcon Inc. (NYSE:ACL), after closing a deal with Nestlé S.A. (EUREX:NESN) for its stake in the Swiss ophthalmic care company.
In a deal that Basel, Switzerland-based Novartis sees as step towards a merger with Alcon, it paid $28.3 billion for 156 million shares of the company, bringing its share to 77 percent.
Alcon Inc. (NYSE:ACL) posted double-digit sales and earnings increases during the second quarter, as revenues rose 12.5 percent and profits rose 15.1 percent.
The Huenenberg, Switzerland-based ophthalmic devices giant reported net earnings of $670 million, or $2.21 per diluted share, on sales of $1.89 billion for the three months ended June 30. That compares with net earnings of $582 million, or $1.94 per diluted share, on sales of $1.68 billion during the same period last year.